WIF1 and nasopharyngeal carcinoma: To identify appropriate NPC epigenetic biomarkers for clinical use, a group of scientists at the University of Hong Kong performed methylation-sensitive resolution melting (MS-HRM) assays to quantitate the methylation states of four hypothetical tumor suppressors, i.e., RASSF1, WIF1, DAPK1, and RARB, in 220 and 50 plasma samples from NPC patients and control individuals, respectively.